Showing 341-350 of 2159 results for "".
- Study Links Vitiligo to Higher Autoimmune and Infection Burden in US Cohorthttps://practicaldermatology.com/news/vitiligo-linked-to-higher-autoimmune-and-infection-burden-in-us-cohort/2486572/New data from a large retrospective study suggested patients with vitiligo experience higher rates of several comorbidities and safety events compared with matched controls. Investigators analyzed Optum Market Clarity EHR dat
- AD-VISE: Better Patient Outcomes Tied to Achieving MDA at 6 Months with Upadacitinibhttps://practicaldermatology.com/news/ad-vise-better-patient-outcomes-tied-to-achieving-mda-at-6-months/2486433/Patients with atopic dermatitis (AD) treated with upadacitinib who achieved minimal disease activity (MDA) demonstrated markedly improved patient-reported outcomes (PROs) compared with those meeting moderate or no treatment targets, according to findings from the r
- FDA Warns Websites Selling Unapproved Botulinum Toxin Productshttps://practicaldermatology.com/news/fda-warns-websites-selling-unapproved-botulinum-toxin-products/2484341/The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including sym
- Dr. Andrew Alexis Highlights 2-MNG as Option to Treat Acne-Related PIHhttps://practicaldermatology.com/news/dr-andrew-alexis-highlights-2-mng-as-option-to-treat-acne-related-pih/2483902/The topical agent 2-Mercaptonicotinoyl glycine (2-MNG), also marketed as Melasyl, could be key to treating acne-related postinflammatory hyperpigmentation (PIH) in skin of color, Andrew Alexis, MD, MPH, said at the Skin of Color Update in New York, New York. Dr. Alexis presented on managin
- Report: IL-17 Therapies Target PsO and More, Poised for Growthhttps://practicaldermatology.com/news/report-il-17-therapies-target-pso-and-more-poised-for-growth/2475920/The interleukin-17 (IL-17) inhibitors market is expected to see sustained growth through 2034, driven primarily by next-gen agents and expanding indications in dermatology and rheumatology, according to a new report. Novel ag
- Nemolizumab Approved by European Commission for Moderate-to-severe Prurigo Nodularishttps://practicaldermatology.com/news/nemolizumab-approved-european-commission-for-moderate-to-severe-prurigo-nodularis/2471164/Nemolizumab has been approved by the European Commission for the treatment of moderate-to-severe prurigo nodularis, according to an announcement from Galderma. The approval of the monoclonal antibody (marketed as Nemluvio) fol
- Illuminate PRP Adds Industry Veteran Redmond as CCOhttps://practicaldermatology.com/news/illuminate-prp-adds-industry-veteran-redmond-cco/2470885/Industry veteran Jennifer Redmond, MBA, joined Illuminate PRP as Chief Commercial Officer, the company announced. “Jennifer brings a wealth of experience in sales and marketing within the aesthetics and pharmaceutical industries, along with strong leadership and a commitment to driving pos
- Allergy-Friendly Detergents Safe for Atopic Dermatitis Patientshttps://practicaldermatology.com/news/allergy-friendly-detergents-safe-atopic-dermatitis-patients/2470779/A recent clinical study found that two laundry detergents marketed for sensitive skin do not negatively impact the skin microbiome or worsen symptoms of atopic dermatitis (AD). The study was conducted in 41 participants diagnosed with AD. For the present study, the researchers evaluated th
- Report: Nonsurgical Aesthetics Revenues Up 9%https://practicaldermatology.com/news/report-nonsurgical-aesthetics-revenues-9/2468303/Data and analytics solutions provider Guidepoint Qsight and investment banking and management consulting firm Skytale Group released a new report on the state of the aesthetics industry, highlighting the continued expansion of the US market. Combined nonsurgical revenues increased by 9% in
- Powered By MRP Gets Series A Investmenthttps://practicaldermatology.com/news/powered-mrp-gets-series-investment/2467442/“Strong tailwinds behind the aesthetics market” was part of the impetus for two prominent growth equity firms to form a strategic partnership with aesthetics device company Powered By MRP, according to a press release. The Series A investment by Aries Capital Partners and Swell Collective